Ophthalmology Licensing Deal Calculator —
benchmark your deal in 60 seconds
Phase 2 ophthalmology deals median ~$50M upfront, ~$700M total. Gene therapy programs (e.g., IRDs) command 3–4x multiples. Built on 1,900+ verified biopharma transactions across 12 therapeutic areas.
Ophthalmology deal benchmarks at a glance
Median deal terms for ophthalmology licensing transactions, by development phase. Data current as of 2026.
| Phase | Median Upfront | Median Total Value | Median Royalty (Tiered) |
|---|---|---|---|
| Preclinical | $30M | $450M | 4–8% |
| Phase 1 | $75M | $750M | 6–12% |
| Phase 2 | $220M | $1.6B | 8–16% |
| Phase 3 | $500M | $3B | 12–22% |
Source: Ambrosia Benchmarker dataset, 1,900+ verified transactions (2017–2026). Primary sources: SEC EDGAR 8-K filings, FTC premerger notifications, ClinicalTrials.gov.
Recent comparable deals
- Roche–Spark ($4.3B, Luxturna)
- AbbVie–REGENXBIO
- Novartis–Gyroscope
Why Ophthalmology is priced this way
Gene therapy and longer-duration anti-VEGF dominate recent ophthalmology dealmaking. Smaller patient populations but high price-per-patient drive deal economics.
Try it live
Run a Ophthalmology deal scenario
Pick your phase, modality, and indication. Get instant benchmark ranges — no signup needed to start.
Quick Benchmark
Live data from 1,900+ deals. Select your parameters:
Ophthalmology licensing — frequently asked
What is the median upfront payment for a Ophthalmology licensing deal?
How are Ophthalmology deal milestones structured?
What royalty rates are typical for Ophthalmology licensing?
Is there a free Ophthalmology deal calculator?
How does Ophthalmology licensing compare to other therapeutic areas?
7-Day Free Trial · No Promo Code
Run unlimited ophthalmology deals — Pro.
Monte Carlo sensitivity, partner matching across 850+ companies, scenario comparison (Bear/Base/Bull rNPV), and board-ready PDF reports. Free for 7 days. Cancel anytime.
Then $299/month · No charge during trial · Cancel anytime